147 related articles for article (PubMed ID: 3089080)
1. [Contracture test with ionophore A 23187 for the diagnosis of malignant hyperthermia].
Moeller R; Kozak-Reiss G; Gascard JP; Laxenaire MC
Ann Fr Anesth Reanim; 1986; 5(2):177-81. PubMed ID: 3089080
[TBL] [Abstract][Full Text] [Related]
2. [Tests of contracture and sensitivity to malignant hyperthermia in 27 patients].
Krivosic-Horber R; Adnet P; Krivosic I; Theunynck D; Guévart E; Adamantidis M
Ann Fr Anesth Reanim; 1988; 7(2):132-8. PubMed ID: 3364812
[TBL] [Abstract][Full Text] [Related]
3. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
4. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
5. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
Larach MG; Landis JR; Bunn JS; Diaz M
Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
[TBL] [Abstract][Full Text] [Related]
6. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
7. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
Allen GC; Larach MG; Kunselman AR
Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
[TBL] [Abstract][Full Text] [Related]
9. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia.
Isaacs H; Badenhorst M
Anesthesiology; 1993 Jul; 79(1):5-9. PubMed ID: 8342829
[TBL] [Abstract][Full Text] [Related]
10. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Sato N; Brum JM; Mitsumoto H; DeBoer GE
Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
[TBL] [Abstract][Full Text] [Related]
11. Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia.
Bendixen D; Ording H
Acta Anaesthesiol Scand; 1990 Nov; 34(8):658-61. PubMed ID: 2275327
[TBL] [Abstract][Full Text] [Related]
12. [Detection of peranesthetic malignant hyperthermia by muscle contracture tests and NMR spectroscopy].
Kozak-Reiss G; Gascard JP; Redouane-Bénichou K
Ann Fr Anesth Reanim; 1986; 5(6):584-9. PubMed ID: 3826791
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
15. In vitro contracture testing for determination of susceptibility to malignant hyperthermia: a methodologic update.
Iaizzo PA; Wedel DJ; Gallagher WJ
Mayo Clin Proc; 1991 Oct; 66(10):998-1004. PubMed ID: 1833602
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
[TBL] [Abstract][Full Text] [Related]
17. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia.
Britt BA; Frodis W; Scott E; Clements MJ; Endrenyi L
Can Anaesth Soc J; 1982 Nov; 29(6):550-62. PubMed ID: 7139394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
